<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04424251</url>
  </required_header>
  <id_info>
    <org_study_id>HSK21542-201</org_study_id>
    <nct_id>NCT04424251</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of HSK21542 in Inducing Postoperative Analgesia in Undergoing Elective Laparoscopic Surgery</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Two-stage Phase II Study Evaluating the Efficacy and Safety of HSK21542 in Inducing Postoperative Analgesia in Subjects Undergoing Elective Laparoscopic Surgery Under General Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haisco Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haisco Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled, two-stage phase II&#xD;
      clinical study. The main objective is to evaluate the efficacy and safety of HSK21542&#xD;
      injection and explore the recommended dose and administration frequency for subsequent Phase&#xD;
      II studies in conjunction with the pharmacodynamic (PD) and pharmacokinetic (PK)&#xD;
      characteristics.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2, 2020</start_date>
  <completion_date type="Actual">April 28, 2021</completion_date>
  <primary_completion_date type="Actual">January 5, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence and severity of AEs</measure>
    <time_frame>From screening up to 4 weeks</time_frame>
    <description>Adverse event/serious adverse event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs: Systolic and Diastolic Blood Pressure</measure>
    <time_frame>From screening up to 4 weeks</time_frame>
    <description>Vital signs (Systolic and Diastolic Blood Pressure) will be collected in subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sum of Pain Intensity Differences (SPID)</measure>
    <time_frame>Frome administration until 24 hours after administration</time_frame>
    <description>The time-weighted sum of pain intensity differences of the rest pain in each group within 0-12 h and 0-24 h after the first postoperative dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of remedial analgesics</measure>
    <time_frame>Frome administration until 24 hours after administration</time_frame>
    <description>Cumulative dose of remedial analgesics (mg of morphine injection) in each group within 0-12 h and 0-24 h after the first postoperative dose, the percentage of subjects in each group who have not used remedial analgesics, and the time to start using remedial analgesics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with a NRS of ≤ 3</measure>
    <time_frame>Frome administration until 24 hours after administration</time_frame>
    <description>The proportion of subjects in each group with a resting pain NRS of ≤ 3 at 12 h and 24 h after the first postoperative dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The plasma concentration</measure>
    <time_frame>-30 minutes before administration until 24 hours after administration</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>HSK21542 0.4 μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative:0.4 μg/kg Postoperative:0.2 μg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HSK21542 1 μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative:1 μg/kg Postoperative:0.5 μg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HSK21542 2 μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative:2 μg/kg Postoperative:1 μg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HSK21542</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative:2 μg/kg Postoperative:1 μg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 0.4 μg/kg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Preoperative:0.4 μg/kg Postoperative:0.2 μg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 1 μg/kg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Preoperative:1 μg/kg Postoperative:0.5 μg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 2 μg/kg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Preoperative:2 μg/kg Postoperative:1 μg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Preoperative:2 μg/kg Postoperative:1 μg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK21542 0.4 μg/kg</intervention_name>
    <description>Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations</description>
    <arm_group_label>HSK21542 0.4 μg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK21542 1 μg/kg</intervention_name>
    <description>Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations</description>
    <arm_group_label>HSK21542 1 μg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK21542 2 μg/kg</intervention_name>
    <description>Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations</description>
    <arm_group_label>HSK21542 2 μg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK21542</intervention_name>
    <description>Once preoperative and once each at 0 and 12 h postoperative, for a total of 3 administrations (adjusted according to the results of the first 3 groups)</description>
    <arm_group_label>HSK21542</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 0.4 μg/kg</intervention_name>
    <description>Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations</description>
    <arm_group_label>Placebo 0.4 μg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 1 μg/kg</intervention_name>
    <description>Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations</description>
    <arm_group_label>Placebo 1 μg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 2 μg/kg</intervention_name>
    <description>Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations</description>
    <arm_group_label>Placebo 2 μg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once preoperative and once each at 0 and 12 h postoperative, for a total of 3 administrations (adjusted according to the results of the first 3 groups)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 ≤ age ≤ 65 years old, with no gender requirement&#xD;
&#xD;
          2. American Society of Anesthesiologists (ASA) Class I-II&#xD;
&#xD;
          3. 18 kg/m^2 ≤ BMI ≤ 30 kg/m^2&#xD;
&#xD;
          4. Subjects undergoing elective laparoscopic surgery under general anesthesia with an&#xD;
             expected surgery duration of 1-5 h (inclusive)&#xD;
&#xD;
          5. Agree to participate in this trial and voluntarily sign the informed consent form;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of allergy to opioids, such as urticaria, or allergic to the intraoperative&#xD;
             anesthetics prescribed in the protocol;&#xD;
&#xD;
          2. History or evidence of any one of the following diseases prior to screening:&#xD;
&#xD;
               1. History of cardiovascular diseases: Uncontrolled hypertension (systolic blood&#xD;
                  pressure [SBP] ≥ 170 mmHg and/or diastolic blood pressure [DBP] ≥ 105 without&#xD;
                  antihypertensive treatment, or SBP &gt; 160 mmHg and/or DBP &gt; 100 mmHg despite&#xD;
                  antihypertensive treatment), aneurysm, severe arrhythmia, heart failure,&#xD;
                  Adams-Stokes syndrome, New York Heart Association (NYHA) Class ≥ III, severe&#xD;
                  superior vena caval syndrome, pericardial effusion, acute myocardial ischemia,&#xD;
                  unstable angina, myocardial infarction in the last 6 months before screening,&#xD;
                  history of tachycardia/bradycardia requiring medication, and II-III degree&#xD;
                  atrioventricular block (excluding patients with pacemakers);&#xD;
&#xD;
               2. History of respiratory disorder: Severe chronic obstructive pulmonary disease,&#xD;
                  acute exacerbation of chronic obstructive pulmonary disease, severe&#xD;
                  bronchostenosis, throat mass, history of (bronchial) tracheoesophageal fistula or&#xD;
                  airway tear, and severe respiratory tract infection in the last 2 weeks before&#xD;
                  screening;&#xD;
&#xD;
               3. History of disorders in the nervous and psychiatric system: History of&#xD;
                  craniocerebral injury, possible convulsions, intracranial hypertension, cerebral&#xD;
                  aneurysms, and history of cerebrovascular accidents; history of schizophrenia,&#xD;
                  mania, mental aberration, long-term use of psychotropic drugs, and cognitive&#xD;
                  disorder; history of depression, anxiety, and epilepsy, etc.;&#xD;
&#xD;
               4. Underwent major surgery within 3 months before screening and was judged by the&#xD;
                  investigator to have potential effect on the postoperative pain evaluation;&#xD;
&#xD;
          3. Any of the following airway management risks during screening:&#xD;
&#xD;
               1. Acute asthma attacks;&#xD;
&#xD;
               2. Sleep apnea syndrome;&#xD;
&#xD;
               3. History or family history of malignant hyperthermia;&#xD;
&#xD;
               4. History of failed tracheal intubation;&#xD;
&#xD;
               5. Difficult airway (modified Mallampati score ≥ III) as determined by the&#xD;
                  investigator;&#xD;
&#xD;
          4. In receipt of any of the following drugs or therapies during the screening period:&#xD;
&#xD;
               1. The time between randomization and the last dose of opioid or non-opioid (such as&#xD;
                  acetaminophen, aspirin [daily dose of &gt; 100 mg], indomethacin, diclofenac,&#xD;
                  parecoxib sodium and other non-steroidal anti-inflammatory drugs) analgesics is&#xD;
                  shorter than 5 half-lives of the drug or the duration of drug efficacy (whichever&#xD;
                  is longer);&#xD;
&#xD;
               2. Continuous use of opioid analgesics for more than 10 days for any reason within 3&#xD;
                  months before screening;&#xD;
&#xD;
               3. Use of drugs that affect the analgesic effect within 14 days before&#xD;
                  randomization, including but not limited to: Sedative hypnotics (benzodiazepines&#xD;
                  [triazolam, diazepam, midazolam, etc.], non-benzodiazepines [zolpidem, zopiclone,&#xD;
                  zaleplon, etc.]), sedative anesthetics (sevoflurane, anesthesia ether, nitrous&#xD;
                  oxide, thiopental, ketamine, etomidate, etc.), glucocorticoids (dexamethasone&#xD;
                  hydrochloride , methylprednisolone, etc.), anti-epilepsy drugs (carbamazepine,&#xD;
                  sodium valproate, etc.), anxiolytics (carbamazepine, diazepam, etc.),&#xD;
                  antidepressants (imipramine, amitriptyline, etc.), and Chinese herbal medicines&#xD;
                  or Chinese patent medicines with analgesic and sedative effects;&#xD;
&#xD;
               4. Expected to receive anti-tumor drugs and treatments during the period from 14&#xD;
                  days before randomization to the end of the follow-up period, including but not&#xD;
                  limited to chemotherapeutic drugs, targeted drugs, and Chinese herbal medicines.&#xD;
&#xD;
               5. The time between randomization and the last use of diuretics and compound drugs&#xD;
                  containing diuretic components is shorter than 5 half-lives of the drug or the&#xD;
                  duration of drug efficacy (whichever is longer);&#xD;
&#xD;
          5. Laboratory test parameters meet one of the following criteria in the screening period&#xD;
             and is confirmed by retests:&#xD;
&#xD;
               1. White blood cell count &lt; 3.0 x 10^9/L;&#xD;
&#xD;
               2. Platelet count &lt; 80 x 10^9/L;&#xD;
&#xD;
               3. Hemoglobin &lt; 80 g/L;&#xD;
&#xD;
               4. Prothrombin time &gt; 1.5 x ULN;&#xD;
&#xD;
               5. Activated partial thromboplastin time &gt; 1.5 x ULN;&#xD;
&#xD;
               6. Alanine aminotransferase and/or aspartate aminotransferase &gt; 2 x ULN;&#xD;
&#xD;
               7. Total bilirubin &gt; 1.5 x ULN;&#xD;
&#xD;
               8. Blood creatinine &gt; 1.5 x ULN;&#xD;
&#xD;
               9. Fasting blood glucose ≥ 11.1 mmol/L;&#xD;
&#xD;
          6. Without oxygen supplement during the screening period, the pulse oxygen saturation is&#xD;
             &lt; 92%;&#xD;
&#xD;
          7. During the screening period, the virological examination for hepatitis B surface&#xD;
             antigen (HBsAg), hepatitis C antibody (HCVAb), treponema pallidum antibody, or human&#xD;
             immunodeficiency virus (HIV) antibody is positive;&#xD;
&#xD;
          8. History of drug abuse, narcotics use and/or alcohol abuse within 3 months before&#xD;
             screening. Alcohol abuse is defined as &gt; 2 units of alcohol consumption per day (1&#xD;
             unit = 360 mL of beer containing 5% alcohol, 45 mL of liquor containing 40% alcohol,&#xD;
             or 150 mL of wine);&#xD;
&#xD;
          9. Donated or lost ≥ 400 mL of blood within 3 months before screening;&#xD;
&#xD;
         10. Participated in any drug clinical trials within 3 months before screening (defined as&#xD;
             the administration of the investigational product or placebo);&#xD;
&#xD;
         11. Women who are pregnant or breastfeeding; fertile women or men who are unwilling to use&#xD;
             contraception during the trial; subjects who are planning pregnancy within 3 month&#xD;
             after the completion of the trial (including male subjects);&#xD;
&#xD;
         12. Subjects determined by the investigator to be unsuitable for participating in this&#xD;
             clinical study for any other reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 3, 2020</study_first_submitted>
  <study_first_submitted_qc>June 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>September 18, 2021</last_update_submitted>
  <last_update_submitted_qc>September 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Agnosia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

